Tumor recurrence is the main limitation of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) and can be promoted by immunosuppressants. However, there is no prevention or treatment for HCC recurrence after LT. Here we describe a clinical-scale method for an adoptive immunotherapy approach that uses natural killer (NK) cells derived from deceased donor liver graft perfusate to prevent tumor recurrence after LT. Liver mononuclear cells (LMNCs) that were extracted from deceased donor liver graft perfusate contained a high percentage of NK cells (45.0 ± 4.0%) compared with peripheral blood mononuclear cells (PBMCs) (21.8 ± 5.2%) from the same donor. The CD69 activation marker and the natural cytotoxicity receptors, NKp44 and NKp46, were expressed at high levels in freshly isolated liver NK cells. Furthermore, interleukin-2 (IL-2)-stimulated NK cells showed greater upregulation of activation markers and the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is critical for NK cellmediated antitumor cell death and increased production of interferon. Moreover, IL-2 stimulation induced LMNCs to exhibit a strong cytotoxicity against NK-susceptible K562 target cells compared with PBMCs (p < 0.01). Finally, we also showed that the final product contained a very low T-cell contamination (0.02 ± 10 6 cells/kg −1 ), which reduces the risk of graft-versus-host disease (GVHD). Collectively, our results suggest that the adoptive transfer of IL-2-stimulated NK cells from deceased donor liver graft perfusate could be a promising treatment for LT patients with HCC.
INTRODUCTION
. However, there is no definitive treatment or prevention for the recurrence of HCC after LT (35, 48) . Hence, alternative therapies are needed for immunosup-Hepatocellular carcinoma (HCC) is one of the most common reasons for liver transplantation (LT). In the pressed HCC patients. Natural killer (NK) cells are the major components past decade, the number of LT for patients with HCC has increased since the Milan criteria for HCC have of innate immunity and the first line of defense against invading infectious microbes and neoplastic cells (38) . been used for organ allocation in the US (16, 23) . However, the rate of recurrence of HCC after LT is 10-20% Functional impairment and decreased numbers of NK cells have been identified in HCC or cirrhotic patients (21, 32) . This recurrence remains the most serious issue for LT in patients with HCC. The necessity of using (1, 5, 17) . These functional defects in the NK cells might be responsible for the failure of antitumor immune postoperative immunosuppressants in the transplant recipient poses an additional risk for recurrence and hin-responses after LT with HCC. Since the immunosuppressive regimen that is currently used after LT reduces ders the use of cytotoxic chemotherapy drugs (14,23, 1398 OHIRA ET AL. the adaptive immune components but effectively main-perfusate was retrieved in our cGMP cell processing facility (4, 9, 37) . Since the UW solution has a high vis-tains the innate components of cellular immunity (12, 13, 24) , augmentation of the NK cell response may cosity (45) , the perfusate was centrifuged at 2,800 × g for 30 min at 4°C in order to ensure adequate centrifuga-be a promising immunotherapeutic approach (28) .
Recently, we characterized the phenotypical and tion. The cell pellet was then subjected to Ficoll-Hypaque density-gradient centrifugation. A cell viability functional properties of liver NK cells extracted from living donor liver graft perfusate (17) . We have also pro-of 90% was ensured by trypan blue exclusion prior to all assays. posed a novel strategy of adjuvant immunotherapy to prevent tumor recurrence after LT. This immunotherapy Cell Culture involves intravenously injecting LT recipients with activated donor liver allograft-derived NK cells. This immu-LMNCs and PBMCs were cultured with 1000 U/ml of human recombinant interleukin-2 (IL-2) (Proleukin, notherapy has been successfully performed in 14 living donor LT recipients at Hiroshima University, Japan (27).
Novartis, Emeryville, CA) in culture medium at 37°C in an atmosphere supplemented with 5% CO 2 . Anti-CD3 Some research groups have shown that deceased donor liver graft contains a unique subset of NK cells monoclonal antibody (mAb) (Orthoclone OKT3, Ortho Biotech, Raritan, NJ) was added to the culture medium (18, 25, 26) . However, the function and characteristics of liver NK cells that are derived from deceased donors and (1 µg/ml) 1 day prior to cell harvesting. After 4 days of culture, the cells were harvested for further analysis. processed for clinical immunotherapy are not well known.
Here, we demonstrated for the first time the phenotypical Testing for lot release included cell counts, viability, Gram stain, and endotoxin. Cell counts and viability and functional properties of liver NK cells that were extracted from deceased donor liver graft perfusate under were performed using the trypan blue dye exclusion method. Test samples were stained with trypan blue and current good manufacturing practice (cGMP) conditions. then microscopically examined with a hematocytometer.
PATIENTS AND METHODS
A minimum of 1 × 10 7 cells with a cell viability of Collection of Samples >80% was required to release the NK cell product for infusion. The Gram staining was performed at the Clini-Fourteen donors who underwent organ recovery for LT were involved in this study. The donors included 11 cal Microbiology Laboratory (Jackson Memorial Hospital, Miami, FL) by using standard methods, with the lot men and 3 women aged 20-71 years (mean age ± SD, 43.4 ± 17.6 years). Informed consent was obtained from release criterion of "no organisms seen." Endotoxin testing by the Limulus Amebocyte Lysate assay was per-each donor, and the study protocol was approved by the Ethics Committee at the University of Miami. Standard formed on the final product by using the Endosafe-PTS (portable test system; Charles River, Wilmington, MA). testing for infectious disease, including assays for the detection of hepatitis B and C and human immunodefi-An endotoxin value of not more than 5 EU/kg was used for lot release. Although not included as a lot ciency virus (anti-HCV, anti-HIV, anti-HBcore, and HBsAg), was performed. A donor who tested positive release criterion, the final product was tested for sterility by collecting specimens for aerobic, anaerobic, and fun-for any of the infectious disease markers listed above was excluded from this study. Peripheral blood (40 ml) gal cultures and inoculating them in vials filled with soybean-casein digest broth and fluid thioglycollate was collected from the organ donors. Subsequently, peripheral blood mononuclear cells (PBMCs) were iso-media (BD Bactec, Becton Dickinson, Sparks, MD). The specimens were cultured for 14 days at 37°C. Myco-lated by Ficoll-Hypaque (GE Healthcare, Sweden) density-gradient centrifugation and resuspended in X-VIVO plasma testing was performed using the VenorGeM Mycoplasma Detection Kit (Sigma-Aldrich, St. Louis, MD). 15 medium (LONZA, Walkersville, MD) supplemented with 100 µg/ml of gentamycin (APP Pharmaceuticals, Flow Cytometry Schaumburg, IL), 10% human AB serum (Valley Biomedical, Winchester, VA), and 10 U/ml of sodium All flow cytometry (FCM) analyses were performed on a FACSCalibur cytometer or LSR II Flow Cytometer heparin (APP Pharmaceuticals, Schaumburg, IL) (culture medium). During organ recovery, the aorta was (BD Biosciences, San Jose, CA). For phenotyping of the surface markers, the leukocytes were stained with the clamped and the liver flushed in situ with up to 4 L of University of Wisconsin (UW) solution to remove blood following monoclonal antibodies (mAbs): fluorescein isothiocyanate (FITC)-conjugated anti-CD3 and anti-from the vasculature. After organ recovery, the liver was placed in a bag and perfused through the portal vein CD15 (BD Biosciences), goat anti-mouse IgG and anti-CD56 (BioLegend, San Diego, CA); phycoerythrin with an additional 2 L of UW solution at the back table. This perfusate was collected from the vena cava and (PE)-conjugated anti-CD16, tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), NKp44, used to study liver mononuclear cells (LMNCs). The NKp46, CD69, CD94, CD25, CD14, CD19, and CD7; experimental 7-AAD + dead targets) − (% spontaneous 7-AAD − dead targets)]/[(100 − (% spontaneous 7-AAD + allophycocyanin (APC)-conjugated anti-CD56 (B159) and CD11b (BD Biosciences); APC-eFluor 780-conju-dead targets)] × 100. gated anti-CD3; eFluor 625-conjugated anti-CD15; bio-Statistical Analysis tin-conjugated anti-CD4; peridinin chlorophyll protein For comparison between two groups, the Student's tcomplex (PerCP)-eFluor 710-conjugated anti-CD11c test (two-tailed) was performed. For comparison of more (eBioscience, San Diego, CA); Qdot565-conjugated than two groups, one-way ANOVA followed by the Stuanti-CD8; Qdot655-conjugated anti-CD19; Alexa Fluor dent-Newman-Keuls post hoc analysis was performed. 568-conjugated streptavidin; and Alexa Fluor 700-A value of p < 0.05 was considered statistically significonjugated anti-CD14 (Invitrogen, Carlsbad, CA). Dead cant. Values are expressed as the mean ± SEM. cells were excluded by light scatter and 7-aminoactinomycin D (7-AAD) or 4′,6-diamidino-2-phenylindole RESULTS (DAPI) (Invitrogen) staining. Cytokine production of Deceased Donor LMNCs Contain a Large Population lymphocytes was measured by a combination of cell surof NK and NT Cells face and cytoplasmic mAb staining according to the manufacturer's instructions. Briefly, 4 h after treatment
As an initial step, we compared the characteristics with Leukocyte Activation Cocktail (BD GolgiPlug, BD between LMNCs and PBMCs derived from deceased Biosciences), the lymphocytes were stained with antidonors to determine whether liver NK cells could be CD3-FITC and anti-CD56-APC surface markers (BD used for clinical immunotherapy. To characterize the Bioscience). After washing, the cells were fixed and perdonor liver and peripheral NK cells, we collected liver meabilized with Cytofix/Cytoperm solution (BD Biograft perfusate and peripheral blood during regular organ sciences) and washed with Perm/Wash Buffer (BD procurement. The liver graft perfusate contained a large Biosciences). Subsequently, aliquots were stained with number of mononuclear cells (1.2 ± 0.2 × 10 9 cells), either a mAb against intracellular cytokines; anti-interwith a viability of 90 ± 3%. The phenotype of these cells feron-γ (IFN-γ)-PE, antitumor necrosis factor-α (TNFwas markedly different from that of matched donor α)-PE, or anti-IL-2-PE (BD Biosciences).
PBMCs (Table 1 ). The proportions of CD3 − CD56 + NK and CD3 + CD56 + natural killer-like T (NT) cells in the Cell Targets
LMNCs were significantly higher than those in the K562, a human chronic myelogenous leukemia cell line (ATCC #CCl-243), was cultured in DMEM medium using the following formula: % cytotoxicity = [(% PBMCs. In contrast, the LMNCs possessed a smaller 6.6-35.2%). After processing, NK cells were enriched to 52.0 ± 5.0%. The viability of the enriched NK cells, number of T cells and B cells than did the PBMCs. There was no significant difference in the number of as determined by trypan blue staining, remained >90% during the process. No microbial contamination was monocytes or granulocytes. Phenotypical flow cytometry analysis of other surface markers was then performed detected in the final product or in the culture medium.
In addition, the cell processing resulted in a significant in a comparative analysis between liver and blood NK cells ( Table 1 ). The CD69 early activation marker was reduction of T cells in the final product. The percentage of CD3 + CD56 − T cells decreased to 0.6 ± 0.2% (0.18 × expressed on the majority (75.0%) of liver NK cells, whereas the same subset in the PBMCs showed a signif-10 5 cells/kg). Other CD56 + components of the final product included NT cells (0.2 ± 0.1%). Next, we fur-icantly lower frequency of expression (9.6%). When the expression of the nonmajor histocompatibility complex ther examined the phenotype of the CD56 − fraction of the final product. After IL-2 stimulation, the phenotype class I-specific-activating NK cell receptors (natural cytotoxicity receptors; NKp44 and NKp46) was exam-of the final product was assessed using another T-cell marker, CD7, with or without the addition of OKT3. As ined in both liver and peripheral blood, nearly all NK cells (>90%) expressed NKp46. In agreement with shown in including T-cell opsonization and clearance by mononuclear phagocytic cells, and complement-mediated cell Both the liver and peripheral blood NK cells expressed the C-type lectin receptor CD94. This molecule binds lysis (6,7,39). The remainder of the T cells (10.3% of the final product) is involved in CD3 internalization or human leukocyte antigen (HLA)-E loaded with leader peptides from major histocompatibility complex (MHC) modulation, which induce T-cell dysfunction (6,36).
Other components of the final product are shown in class I molecules (10).
Next, we analyzed the response of NK cells in Table 2 .
For phenotypically characterizing the NK cells in the LMNCs and PBMCs after IL-2 stimulation. TRAIL is a type II transmembrane protein that belongs to the TNF final product relative to those in the starting material, a detailed flow cytometry analysis was undertaken. As family, which preferentially induces apoptotic cell death in a wide variety of tumor cells but not in most normal shown in Figure 2 , freshly isolated liver NK cells barely expressed TRAIL, NKp44, and CD25 (IL-2αR) and pro-cells (30, 43, 44) . We previously reported that in vitro IL-2 stimulation upregulated the expression of TRAIL and duced little cytokines. The cell processing significantly upregulated the expression of TRAIL and NKp44 in induced strong cytotoxicity for liver NK cells extracted from living donor liver graft perfusate (17). As shown liver NK cells, but these changes were not seen in peripheral blood NK cells. The expression of CD69 and in Figure 1 , freshly isolated liver NK cells and peripheral blood NK cells barely expressed TRAIL. Stimula-CD25 in liver NK cells also increased, but not significantly. In contrast, NKp46 expression significantly tion with IL-2 significantly upregulated the expression of TRAIL in liver NK cells, but this effect was barely decreased after the cell processing. The activating receptors are defined by their ability to directly mediate the observed for peripheral blood NK cells. IL-2 stimulation also resulted in an increased expression of the activation killing of the targets. Nevertheless, recent findings have demonstrated that the activation of some of the NK-trig-molecule NKp44 and maintained the expression of the inhibitory receptor CD94. These results indicate that gering receptors requires the synergistic stimulation of more than one receptor (3). Our results are compatible cultivated NK cells have a compensatory mechanism to protect the self-MHC class I-expressing cells from NK with this theory. Intracellular staining flow cytometry showed that IL-2 stimulation induced significant cyto-cell-mediated cell death.
kine production [IFN-γ and TNF-α (5.8-37.0% and Characteristics of the Liver NK Cell-Enriched Product 4.1-59.2%, respectively, n = 4, p < 0.01)] in liver NK cells (Fig. 2) . These results are similar to those of stud-For determining whether NK cells from deceased donor liver graft perfusate could be processed using ies of living donor liver graft perfusate (17,27). Next, NK cell cytotoxicity assays using LMNCs and PBMCs cGMP-compliant components, the LMNC cultivation was analyzed. At the start of the culture (preculture), the isolated from the deceased donor as effectors and K562 as targets were performed. Cytotoxicity against the stan-mean percentage of NK cells was 45.0% (range: 21.2-76.2%), whereas T cells constituted 22.8% (range: dard NK cell target K562 was markedly elevated using effector cells from the final products relative to those from precultured LMNCs and PBMCs (Fig. 3) . At a 20: methods for processing different products (4, 9) . Lot section and is as dictated by the FDA guidelines for cel-This study demonstrated that deceased donor liver graft perfusate contained an average of 1.2 ± 0.2 × 10 9 mono-lular products. First, LMNCs were shown to contain a large number of NK and NT cells, with both cell types nuclear cells and 5.3 × 10 8 NK cells, whereas living donor liver graft perfusate, which contained 9.1 ± 0.8 × 10 8 possessing characteristics different from those of PBMCs. Second, in vitro stimulation with IL-2 induced mononuclear cells (Ohdan H et al., Hiroshima University, Japan, unpublished data). However, this number is several liver NK cells to strongly upregulate activation markers, cytotoxicity, and cytokine production and to maintain fold higher than the numbers calculated in previous studies on deceased donor liver perfusate (2, 18, 25) . This dis-the expression of inhibitory receptors. These results were compatible with those for living donor liver graft crepancy may be due to the fact that we collected the liver perfusate at the time of organ procurement while others perfusate (17). Finally, we confirmed that the final product met the lot release criteria and contained low T cell did so just before liver transplantation. NK cells can destroy many solid tissue-derived numbers, thereby reducing the possibility of GVHD in a recipient. malignant cells through death receptor-ligand interactions (42). Previously, we found that normal hepatocytes "immunoediting" (19) . Mice that lack either IFN-γ or its functional receptor are more susceptible to both viral express TRAIL-DR4 and TRAIL-DR5 together with TRAIL-DcR1 and TRAIL-DcR2, but that moderately or and bacterial infections, indicating that IFN-γ plays an important role in antiviral and antibacterial responses poorly differentiated HCCs highly express TRAIL-DR4 and TRAIL-DR5 but do not express TRAIL-DcR1 and (33, 47) . It is possible that these liver NK cells can prevent the replication of viruses including hepatitis C virus TRAIL-DcR2, which indicates a susceptibility to TRAIL-expressing NK cell-mediated activity toward through an IFN-γ-dependent mechanism. Further studies are required to address this possibility. HCC (17, 28) . We have now shown that IL-2 stimulation significantly increases the expression of TRAIL in liver The induction of GVHD is a major risk factor associated with the use of lymphocyte infusions from unre-NK cells that are extracted from deceased donor liver graft perfusate (Fig. 1) . Functionally, we also have lated or haploidentical family donors (8, 15) . For clinical-scale experiments, OKT3 was added to the cul-shown that IL-2-activated liver NK cells were highly cytotoxic against tumors compared with PBMCs ( Fig. ture media 1 day prior to cell harvesting. The administration of OKT3-coated T cells in vivo has been shown 3). In addition to having an antineoplastic effect, NK cells are important components of the innate immune to result in the opsonization and subsequent trapping or lympholysis of cells by the reticuloendothelial system response due to their ability to lyse virus-infected cells and to recruit cells involved in adaptive immune (6, 7, 39) . This method has been performed for clinical NK therapy in Japan, with no GVHD cases reported responses. IFN-γ is a known host mediator that shapes the tumor phenotypes in a broader process known as (27) . Our final product from the cadaveric donor liver T-cell dose was 0.18 × 10 6 cells/kg and that GVHD S. Functional impairment in circulating and intrahepatic natural killer (NK) cells and relative mechanism in hepa-did not occur after haploidentical NK cell infusion (24) . 
